secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-106591
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella announces QTORIN pitavastatin for DSAP; Phase 2 trial planned H2 2026
------------------------------------------------------------------------------

- New candidate targets DSAP, a rare genetic skin disease with no FDA-approved therapies.
- DSAP affects an estimated >50,000 diagnosed U.S. patients and is premalignant.
- Company plans to meet FDA in H1 2026; Phase 2 trial initiation expected H2 2026.
- QTORIN pitavastatin designed to inhibit the mevalonate pathway, the causal driver of DSAP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000110465925106591/0001104659-25-106591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000110465925106591/tm2530285d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-106591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer